DESIGN APPROACHES FOR CURRENT AND FUTURE HIV PREVENTION EFFICACY TRIALS
VIRTUAL WORKSHOP SERIES
OCTOBER 2020 TO JANUARY 2021
#HIVPxTrialDesign
#HIVPxTrialDesign
HIV prevention is evolving rapidly with the roll out of new tools such as pre-exposure prophylaxis (PrEP) and treatment as prevention making a significant contribution towards controlling the epidemic.
As a result, the design and conduct of the next generation of prevention trials is impacted and is further affected by the outcomes of ongoing HIV prevention efficacy trials – including oral and injectable antiretrovirals, passively infused monoclonal antibodies, and HIV vaccines.
The first session of the virtual workshop aims to reflect on current trial designs and lessons learned (introductory talks). This session is supported by six bite-size presentations and a panel discussion of the current scientific approaches for establishing efficacy of vaccines in the broader context or Pre-Exposure Prophylaxis (PrEP).
Help us framing the live conversation on 27 October 2020 by watching these bite-size talks and submitting your questions and comments ahead of time using the link under each presentation. You can also email us directly at Enterprise@Iasociety.org and of course get in touch if you need help navigating the event.
To join the live session please pre-register using the button below.
Presentation | Presenter |
---|---|
An introduction to the workshop organization and agenda. | Roger Tatoud, Ph.D. – International AIDS Society – Geneva, Switzerland. |
Introductory talk – setting the stage | Linda Gail Bekker, MBChB DTMH DCH FCP (SA) PhD – Desmond Tutu HIV Centre – Cape Town, South Africa. |
PrEP Considerations for the MOSAICO Trial | Susan Buchbinder, MD – Bridge HIV at the San Francisco Department of Health |
Community-Informed Efforts Towards the MOSAICO Study | Stephaun Wallace, Ph.D., M.S. – Fred Hutchinson Cancer Research Center – University of Washington – Seattle, USA. |
HPTN 083: Where did we go right? | Raphael Landovitz, M.D. – University of California, San Francisco – San Francisco, USA. |
Contingency Plans: Modelling effectiveness using placebo counterfactuals | Deborah Donnell, Ph.D. – Fred Hutchinson Cancer Research Center – University of Washington – Seattle, USA. |
PrEPVacc concepts – Registrational cohort and prequalification period | Eugene Ruzagira, MBChB, MPH, PhD – MRC/UVRI and LSHTM Uganda Research Unit – Entebbe, Uganda. |
Pre-randomization information can inform counterfactual estimation | David Glidden MD – University of California, San Francisco – San Francisco, USA. |
Susan Buchbinder, MD
University of California San Francisco, USA.
An introduction to the scientific and ethical rational supporting the conduct of the MOSAICO study. For further information on the MOSAICO study, visit the study website.
Submit your questions here.
Stephaun Wallace, Ph.D, M.S.
Fred Hutchinson Cancer Research Center – University of Washington – Seattle, USA.
In this presentation Stephaun Wallace stresses the importance and benefits of community-informed involvement in the design and implementation of the MOSAICO study.
Submit your questions here.
Raphael Landovitz, MD
University of California, USA.
Raphael Landovitz tells us what went right in the HPTN 083 study of the long acting antiviral Cabotegravir. New data are presented and emphasis is put on adhering to scientifically rigorous principles and persevering despite the retention challenge. For further information the HPTN 083 trial, visit the study website.
Submit your questions here.
Deborah Donnell, Ph.D.
Fred Hutchinson Cancer Research Center – University of Washington – Seattle, USA.
Deborah Donnell presents the contingency plans based on a counterfactual approach that were designed should both products tested in HPTN 083 be equally successful and the trial might not have achieved a clear non-inferiorly result.
Submit your questions here.
Eugene Ruzagira, MBChB, MPH, Ph.D.
MRC/UVRI Uganda Research Unit, Entebbe, Uganda.
In this presentation, Eugene Ruzagira outlines the protocol of the Multi Arms Multi Steps (MAMS) PrEPVacc study, the first efficacy trial to test a prophylactic vaccine and PrEP at the same time and that uses a dedicated registration cohort to estimate HIV incidence in the study population. To find out more about the PrEPVacc trial, visit the study website.
Submit your questions here.
David Glidden, Ph.D.
University of California San Francisco, San Francisco, USA.
Following on Eugene Ruzagira presentation of the PrEPVacc efficacy trial, David Glidden discusses the study design and the use of a registration cohort to approximate a control group. Other designs, such as the regency design, are also discussed.
Submit your questions here.
Established in 2003, the Global HIV Vaccine Enterprise (the Enterprise) became a programme of IAS – the International AIDS Society – in 2018. The Enterprise unites stakeholders to share knowledge, foster collaboration, enable solutions and expand support critical to the development of – and future access to – an HIV vaccine.
IAS – the International AIDS Society
Avenue de France 23
CH-1202 Geneva
Switzerland
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
OKLearn moreWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy policy